OUR STRATEGY
Our investment strategy involves partnering with companies that have a proven track record of developing groundbreaking technologies and products. We provide the capital, expertise and support they need to achieve their goals, with a focus on creating long-term value for our investors and contributing to the advancement of life-changing technologies and products that benefit society.
At MintPharma Capital, we are committed to investing in companies that have the potential to create significant value for our investors while also making a positive impact on society. We are passionate about supporting companies developing first to market therapies and devices solving the world's most pressing medical challenges, from new treatments for severe diseases to cutting-edge medical device technologies.
FUND OVERVIEW
-
MintPharma Capital strongly believes reducing the cost of care coupled with clear clinical efficacy and safety will drive formulary and commercial success in a more pronounced way then in years past.
-
MintPharma Capital uniquely offers portfolio companies expertise and experience from seasoned Pharma and Device executives mentoring. Strong regulatory, IP and clinical experience and governance support of portfolio companies.
-
We believe that pre-clinical and early-stage clinical biotech and pharmaceutical companies have the potential for outsized gains, if successful.
TIMING
-
Over the past ten years, pharmaceutical and biotech commercial launches by small and mid-sized companies have been historically less successful in generating meaningful revenue.
-
Insurance companies have significantly restricted their drug benefit formularies through technology while also increasing rebates (on average 50% or more) for formulary access, lowering patient co-pay assistance, and covering new, very expensive, drugs for life-threatening diseases and rare diseases.
-
At the same time insurance companies are achieving record profits through pharmacy benefit management and significantly restricting branded (non-generic) drug and therapeutic utilization.
-
We expect this trend to continue and are targeting specific therapies and devices that should be successful in this new restricted environment and have the potential for commercial success driving outsized gains.
-
MintPharma Capital will target investment opportunities attempting to treat disease states that currently do not have an FDA approved therapy with the potential to reduce the cost of care.